Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

Abroad (travel likely)RecruitingPHASE2

Conditions

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chinese PLA General Hospital, Beijing, Beijing Municipality, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

DLBCL

Abroad (travel likely)RecruitingPHASE1, PHASE2

Rotterdam, Netherlands

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Diffuse Large B-Cell Lymphoma · Chronic Lymphocytic Leukemia · Follicular Lymphoma

IsraelRecruitingPHASE1

Tucson, United States · Miami, United States

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

Non Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Dallas, United States